{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:14:31Z","timestamp":1788963271183,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13318-019-00575-7","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T14:03:05Z","timestamp":1568642585000},"page":"27-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects"],"prefix":"10.1007","volume":"45","author":[{"given":"Daniela","family":"Willen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wolna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orestis","family":"Papasouliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-2794","authenticated-orcid":false,"given":"\u00d6zkan","family":"Yalkinoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"issue":"1","key":"575_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319.","journal-title":"Int Rev Immunol"},{"issue":"2","key":"575_CR2","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/ar2959","volume":"12","author":"SR Dillon","year":"2010","unstructured":"Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator\/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12(2):R48.","journal-title":"Arthritis Res Ther"},{"issue":"5537","key":"575_CR3","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111\u20134.","journal-title":"Science"},{"issue":"5","key":"575_CR4","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","volume":"111","author":"E Belnoue","year":"2008","unstructured":"Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111(5):2755\u201364.","journal-title":"Blood"},{"issue":"7","key":"575_CR5","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","volume":"118","author":"T Matthes","year":"2011","unstructured":"Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118(7):1838\u201344.","journal-title":"Blood"},{"issue":"6","key":"575_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/eji.201746934","volume":"47","author":"P Haselmayer","year":"2017","unstructured":"Haselmayer P, Vigolo M, Nys J, Schneider P, Hess H. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells. Eur J Immunol. 2017;47(6):1075\u201385.","journal-title":"Eur J Immunol"},{"issue":"4","key":"575_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/eji.201646630","volume":"47","author":"NL Tran","year":"2017","unstructured":"Tran NL, Schneider P, Santiago-Raber ML. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus. Eur J Immunol. 2017;47(4):713\u201323.","journal-title":"Eur J Immunol"},{"issue":"2","key":"575_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","volume":"15","author":"JA Gross","year":"2001","unstructured":"Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2):289\u2013302.","journal-title":"Immunity"},{"issue":"6","key":"575_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/ard.2008.090928","volume":"68","author":"J Morel","year":"2009","unstructured":"Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(6):997\u20131002.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"575_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","volume":"26","author":"G Xin","year":"2013","unstructured":"Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2013;26(4):683\u201390.","journal-title":"J Nephrol"},{"issue":"6","key":"575_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"575_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","volume":"25","author":"MV Jonsson","year":"2005","unstructured":"Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren\u2019s syndrome. J Clin Immunol. 2005;25(3):189\u2013201.","journal-title":"J Clin Immunol"},{"issue":"11","key":"575_CR13","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"575_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"575_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","volume":"63","author":"A Munafo","year":"2007","unstructured":"Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63(7):647\u201356.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"575_CR16","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1002\/art.23047","volume":"56","author":"M Dall\u2019Era","year":"2007","unstructured":"Dall\u2019Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142\u201350.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"575_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0961203309102803","volume":"18","author":"C Pena-Rossi","year":"2009","unstructured":"Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547\u201355.","journal-title":"Lupus"},{"issue":"1","key":"575_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/jps.21839","volume":"99","author":"I Nestorov","year":"2010","unstructured":"Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci. 2010;99(1):524\u201338.","journal-title":"J Pharm Sci"},{"issue":"4","key":"575_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-07-4435","volume":"14","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2008;14(4):1105\u201310.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"575_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/0091270008315312","volume":"48","author":"I Nestorov","year":"2008","unstructured":"Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol. 2008;48(4):406\u201317.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"575_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","volume":"101","author":"JF Rossi","year":"2009","unstructured":"Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouille V, et al. Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom\u2019s macroglobulinemia: a phase I study. Br J Cancer. 2009;101(7):1051\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"575_CR22","first-page":"9","volume":"22","author":"K Berelowitz","year":"2011","unstructured":"Berelowitz K, Taubel J. Early phase Japanese bridging studies\u2014global significance and CRO selection criteria. CRfocus. 2011;22(3):9\u201313.","journal-title":"CRfocus"},{"key":"575_CR23","unstructured":"Bhupathi C, Vajjha VH. Sample size recommendation for a bioequivalent study. Statistica. 2017;77:65\u201371."},{"key":"575_CR24","unstructured":"European Medicines Agency. VICH GL 52: bioequivalence: blood level bioequivalence study. London: European Medicines Agency; 2015."},{"issue":"1","key":"575_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","volume":"8","author":"J Hummel","year":"2009","unstructured":"Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8(1):38\u201349.","journal-title":"Pharm Stat"},{"issue":"suppl 2","key":"575_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/annrheumdis-2015-eular.3504","volume":"74","author":"O Papasouliotis","year":"2015","unstructured":"Papasouliotis O, Yalkinoglu \u00d6, Golob M, Willen D, Girard P. Population pharmacokinetics of atacicept in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2015;74(suppl 2):1077 (Abstract).","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"575_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573\u201391.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"575_CR28","unstructured":"Statistics Bureau Japan. Ministry of Internal Affairs and Communications website: weight by age and sex (1900\u20132004). 2004. Available from: \nhttp:\/\/www.stat.go.jp\/english\/data\/chouki\/24.htm\n\n. Accessed 20 December 2016."},{"key":"575_CR29","series-title":"Nutritional status (anthropometry and blood analytes), blood pressure and physical activity","volume-title":"The national diet and nutrition survey: adults aged 19 to 64 years","author":"D Ruston","year":"2004","unstructured":"Ruston D, Hoare J, Henderson L, Gregory J, Bates CJ, Prentice A, et al. The national diet and nutrition survey: adults aged 19 to 64 years, vol. 4. Nutritional status (anthropometry and blood analytes), blood pressure and physical activity; 2004. London: The Stationery Office."},{"issue":"4","key":"575_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803\u201319.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"575_CR31","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","volume":"63","author":"RF van Vollenhoven","year":"2011","unstructured":"van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1782\u201392.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"575_CR32","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/art.39262","volume":"67","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Wax S, Li Y, Tak PP. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol. 2015;67(11):2828\u201336.","journal-title":"Arthritis Rheumatol"},{"issue":"suppl","key":"575_CR33","first-page":"10","volume":"67","author":"C Dascalu","year":"2015","unstructured":"Dascalu C, Davidson A, Mackay MC, Furie R, Huang W, Aranow C. The effect of belimumab on peripheral blood cells in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(suppl):10.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"575_CR34","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328\u201337.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"575_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201\u201310.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"575_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"PP Tak","year":"2008","unstructured":"Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61\u201372.","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00575-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00575-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T23:34:45Z","timestamp":1600126485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00575-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00575-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"16 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Merck KGaA, Darmstadt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniela Willen, Wolfgang Uhl and Peter Wolna were employees of Merck KGaA, Darmstadt, Germany at the time of this study. \u00d6zkan Yalkinoglu is an employee of Merck KGaA, Darmstadt, Germany. Orestis Papasouliotis is an employee of Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The protocol was approved by the Office for Research Ethics Committees Northern Ireland and the study was conducted at the Quintiles Drug Research Unit, Guy\u2019s Hospital, in the UK (EudraCT ID: 2013-002703-34; study: EMR 700461-022), in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, the European Union Clinical Trial Directive, and all applicable local regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Atacicept is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. Therefore, there is no plan for data sharing at this point in time. Please note that for all new products or new indications approved in both the European Union and the United States after January 1, 2014, Merck will share patient level, study level data after de-identification, as well as redacted study protocols and clinical study reports from clinical trials in patients. These data will be shared with qualified scientific and medical researchers, upon researcher\u2019s request, as necessary for conducting legitimate research. Such requests must be submitted in writing to the company\u2019s data sharing portal and will be internally reviewed regarding criteria for researcher qualifications and legitimacy of the research purpose ().","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}